Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
Publication
, Journal Article
James, SK; Pieper, KS; Cannon, CP; Storey, RF; Becker, RC; Steg, PG; Wallentin, L; Harrington, RA; PLATO study group,
Published in: Stroke
May 2013
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Stroke
DOI
EISSN
1524-4628
ISSN
0039-2499
Publication Date
May 2013
Volume
44
Issue
5
Start / End Page
1477 / 1479
Related Subject Headings
- Treatment Outcome
- Ticlopidine
- Ticagrelor
- Thrombosis
- Stroke
- Secondary Prevention
- Purinergic P2Y Receptor Antagonists
- Platelet Aggregation Inhibitors
- Neurology & Neurosurgery
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
James, S. K., Pieper, K. S., Cannon, C. P., Storey, R. F., Becker, R. C., Steg, P. G., … PLATO study group, . (2013). Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke, 44(5), 1477–1479. https://doi.org/10.1161/strokeaha.111.000514
James, Stefan K., Karen S. Pieper, Christopher P. Cannon, Robert F. Storey, Richard C. Becker, Philippe Gabriel Steg, Lars Wallentin, Robert A. Harrington, and Robert A. PLATO study group. “Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.” Stroke 44, no. 5 (May 2013): 1477–79. https://doi.org/10.1161/strokeaha.111.000514.
James SK, Pieper KS, Cannon CP, Storey RF, Becker RC, Steg PG, et al. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013 May;44(5):1477–9.
James, Stefan K., et al. “Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.” Stroke, vol. 44, no. 5, May 2013, pp. 1477–79. Epmc, doi:10.1161/strokeaha.111.000514.
James SK, Pieper KS, Cannon CP, Storey RF, Becker RC, Steg PG, Wallentin L, Harrington RA, PLATO study group. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013 May;44(5):1477–1479.
Published In
Stroke
DOI
EISSN
1524-4628
ISSN
0039-2499
Publication Date
May 2013
Volume
44
Issue
5
Start / End Page
1477 / 1479
Related Subject Headings
- Treatment Outcome
- Ticlopidine
- Ticagrelor
- Thrombosis
- Stroke
- Secondary Prevention
- Purinergic P2Y Receptor Antagonists
- Platelet Aggregation Inhibitors
- Neurology & Neurosurgery
- Humans